VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
15.09.2022 - VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million ... Seite 1